Aprocitentan
FDA-approved product (tablet, oral), marketed as Tryvio.
- Registered studies
- 14
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Hypertension
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antihypertensives
- FDA pharmacologic class
- Endothelin Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
14registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Aprocitentan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension
NCT07635914 · start 2026-05-31
Registered record
- Registry ID
- NCT07635914
- Conditions
- Resistant Hypertension
- Interventions
- Aprocitentan tablets(SYH9108); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Not yet recruiting
- Start
- 2026-05-31
- Completion
- 2030-05-31
- Enrolment
- 382
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionResistant HypertensionInterventionAprocitentan tablets(SYH9108); PlaceboPhasePhase 3Registry statusNot yet recruitingA Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
NCT06799884 · start 2025-01-18
Registered record
- Registry ID
- NCT06799884
- Conditions
- Drug Drug Interaction
- Interventions
- Ethinyl Estradiol / Levonorgestrel Oral Tablet; Aprocitentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2025-01-18
- Completion
- 2025-02-21
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug Drug InteractionInterventionEthinyl Estradiol / Levonorgestrel Oral Tablet; AprocitentanPhasePhase 1Registry statusCompletedBioequivalence Study of Different Aprocitentan Tablet Formulations
NCT05196399 · start 2022-02-02
Registered record
- Registry ID
- NCT05196399
- Conditions
- Healthy Subjects
- Interventions
- Aprocitentan (Formulation A); Aprocitentan (Formulation B)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2022-02-02
- Completion
- 2022-04-07
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionAprocitentan (Formulation A); Aprocitentan (Formulation B)PhasePhase 1Registry statusCompletedThe Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
NCT04252495 · start 2020-06-26
Registered record
- Registry ID
- NCT04252495
- Conditions
- Hepatic Impairment; Healthy Subjects
- Interventions
- Aprocitentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2020-06-26
- Completion
- 2021-05-06
- Enrolment
- 17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatic Impairment; Healthy SubjectsInterventionAprocitentanPhasePhase 1Registry statusCompletedTo Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
NCT04281342 · start 2020-01-14
Registered record
- Registry ID
- NCT04281342
- Conditions
- Healthy Subjects
- Interventions
- Aprocitentan 25 mg; Aprocitentan 100 mg; Matching placebo; Moxifloxacin control to establish assay sensitivity
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2020-01-14
- Completion
- 2021-09-03
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionAprocitentan 25 mg; Aprocitentan 100 mg; Matching placebo; Moxifloxacin control to establish assay sensitivityPhasePhase 1Registry statusCompletedA Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
NCT04162366 · start 2020-01
Registered record
- Registry ID
- NCT04162366
- Conditions
- Hypertension; Renal Insufficiency, Chronic
- Interventions
- Aprocitentan 25 mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2020-01
- Completion
- 2021-07-15
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; Renal Insufficiency, ChronicInterventionAprocitentan 25 mg; PlaceboPhasePhase 3Registry statusWithdrawnA Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
NCT03586570 · start 2018-07-17
Registered record
- Registry ID
- NCT03586570
- Conditions
- Healthy Subjects
- Interventions
- Aprocitentan 25mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-07-17
- Completion
- 2018-09-10
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionAprocitentan 25mg; PlaceboPhasePhase 1Registry statusCompletedA Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
NCT03541174 · start 2018-06-18
Registered record
- Registry ID
- NCT03541174
- Conditions
- Resistant Hypertension
- Interventions
- Aprocitentan 12.5 mg; Aprocitentan 25 mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2018-06-18
- Completion
- 2022-04-25
- Enrolment
- 730
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionResistant HypertensionInterventionAprocitentan 12.5 mg; Aprocitentan 25 mg; PlaceboPhasePhase 3Registry statusCompletedA Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)
NCT03245229 · start 2017-08-10
Registered record
- Registry ID
- NCT03245229
- Conditions
- Healthy Subjects
- Interventions
- Aprocitentan; Rosuvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-08-10
- Completion
- 2017-09-18
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionAprocitentan; RosuvastatinPhasePhase 1Registry statusCompletedA Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease
NCT03165071 · start 2017-06-03
Registered record
- Registry ID
- NCT03165071
- Conditions
- Severe Renal Impairment; Healthy Subjects
- Interventions
- ACT-132577
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-06-03
- Completion
- 2017-10-27
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSevere Renal Impairment; Healthy SubjectsInterventionACT-132577PhasePhase 1Registry statusCompletedA Study to Evaluate ACT-132577 in Healthy Male Subjects
NCT03100591 · start 2017-03-28
Registered record
- Registry ID
- NCT03100591
- Conditions
- Healthy Subjects
- Interventions
- 14C-radiolabeled ACT-132577
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-03-28
- Completion
- 2017-04-18
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsIntervention14C-radiolabeled ACT-132577PhasePhase 1Registry statusCompletedA Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects
NCT02841761 · start 2016-07-01
Registered record
- Registry ID
- NCT02841761
- Conditions
- Healthy Subjects
- Interventions
- Midalozam; Aprocitentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-07-01
- Completion
- 2016-10-01
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionMidalozam; AprocitentanPhasePhase 1Registry statusCompletedClinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects
NCT02708004 · start 2016-06-01
Registered record
- Registry ID
- NCT02708004
- Conditions
- Healthy Subjects
- Interventions
- Aprocitentan; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-06-01
- Completion
- 2016-12-01
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionAprocitentan; PlaceboPhasePhase 1Registry statusCompletedDose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
NCT02603809 · start 2015-12-14
Registered record
- Registry ID
- NCT02603809
- Conditions
- Essential Hypertension
- Interventions
- Aprocitentan 5 mg; Aprocitentan 10 mg; Aprocitentan 25 mg; Aprocitentan 50 mg; Lisinopril 20 mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-12-14
- Completion
- 2017-04-07
- Enrolment
- 1,659
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential HypertensionInterventionAprocitentan 5 mg; Aprocitentan 10 mg; Aprocitentan 25 mg; Aprocitentan 50 mg +2 morePhasePhase 2Registry statusCompleted